AI brief
Enveda raised $311 million, valuing the AI biotech at $2 billion. It is currently testing drugs for skin conditions and for preserving weight loss after stopping GLP-1s.
Why it matters: The funding supports moving more nature-derived AI-discovered drugs into clinical trials.
Written by AI from TechCrunch AI's published text. Read the original for full details.